Matrix3™: Infection Control. Amplified.

Introducing Matrix3™:

The world’s first broad-spectrum triple synergy antibiotic for improved infection control.

Andira Pharmaceuticals has improved the antimicrobial power of silver over 1,000,000-fold by applying synergistic amplification. This amplified form of silver, Matrix3TM, is the world’s first broad-spectrum triple synergy antibiotic for improved infection control.  Matrix3TM is positioned to replace conventional silver that is incorporated into medical products worldwide. Currently, there is a $1 Bn global market for antimicrobial silver wound care products which is projected to grow substantially.

Andira is uniquely positioned to raise the standard of infection control by:

  • Being the only company with two protected triple synergy technologies that incorporate and amplify FDA-approved infection control agents that have established global markets
  • Completing market-enabling studies on Matrix3TM Shield, Andira’s advanced wound care product line for Surgical Site Infection (SSI), proven to have over 1,000,000 times improved anti-bacterial efficacy vs. conventional silver
  • Protecting its technologies with patent coverage, with one US patent granted and 22 patents pending globally

The Market Need for Improved Infection Control

The estimated direct annual cost of treating healthcare-associated infections (HAI) in the United States ranges from $28.4 billion to $45 billion.1 Antimicrobial-resistant ‘superbug’ infections have mortality rates as high as 40% and cost up to $124,000 per case.2,3 Methicillin-Resistant Staph aureus (MRSA) is a leading cause of HAI and an alarming 5% of Americans are now carriers of the superbug with potential to infect others.4 In spite of modern infection control practices, 1 in 4 abdominal surgery patients will develop a Surgical Site Infection (SSI).5

Conventional medical products with imbedded antimicrobial silver, such as medical catheters, wound coverings and topical drugs, lack efficacy for infection control,6-9 yet they remain the standard-of-care globally as reported by top-level medical research. There is a substantial market opportunity for improved infection control products in healthcare settings.

Scientific studies performed in accordance with FDA test protocols demonstrate the dramatically improved efficacy of Matrix3TM Shield, , compared to conventional silver, against top surgical site infection-causing bacteria. 


(Methicillin-Resistant Staph aureus)

* too few to count

E. coli

* too few to count


* too few to count


* too few to count

Matrix3™ Shield:

Andira’s product line for Surgical Site Infection (SSI) made with Matrix3™ technology.

  • Despite modern infection control practices, 1 in 4 abdominal surgery patients will develop a Surgical Site Infection (SSI)2
  • Matrix3TM Shield is a next-generation advanced wound care product line for the prevention and treatment of SSI
  • Designed to compete directly with a top-selling silver wound care line
  • $1 billion USD global market for antimicrobial silver wound care products
  • Matrix3TMShield offers over 1,000,000 times superior anti-bacterial performance than conventional silver, faster onset of action, as well as improved comfort and wound fluid absorbency.
  • Matrix3TMShield rapidly eliminates the top surgical site infection-causing bacteria, including multi-drug resistant bacteria.
  • Scientific results on Matrix3TMShield products are shown above. For additional supporting information or investors data room, please contact us.  


Synergistic Mechanism of Action

CBC and CBG cannabinoids work synergistically with silver to rapidly destroy bacteria, including those that are protected by a double cell wall (Gram-negative bacteria).

First, silver binds to the outer bacterial cell wall, causing structural damage. Next, CBC and CBG gain entry to the bacteria through the damaged outer wall and proceed to target the inner bacterial membrane, causing disruption of membrane integrity. Having both the outer and inner protective layers compromised is lethal to the bacteria. Additionally, the silver particles release silver ions which penetrate the bacteria and cause further damage to intracellular components, such as bacterial DNA.

By acting together through these mechanisms, Matrix3TM components mount a simultaneous attack on both bacterial protective layers while also directing damage inside the bacterial cells. This proven triple synergy action dramatically increases the efficacy of silver, delivering rapid and powerful anti-bacterial protection. For supporting information or other inquiries about Matrix3TM technology, please contact us.

  1. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert review of pharmacoeconomics & outcomes research. 2009;9(5):417–22. doi: 10.1586/erp.09.53 PMC2827870.
  2. Rottier, W. C., Pinholt, M., et al. Dutch VRE Bacteremia Investigators, & Danish Collaborative Bacteraemia Network (DACOBAN) (2022). Attributable mortality of vancomycin resistance in ampicillin-resistant Enterococcus faecium bacteremia in Denmark and the Netherlands: A matched cohort study. Infection control and hospital epidemiology, 43(6), 719–727.
  3. Puchter L, Chaberny IF, Schwab F, Vonberg RP, Bange FC, Ebadi E. Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. Antimicrob Resist Infect Control. 2018 Jan 5;7:1.
  4. Alkaaki A, Al-Radi OO, Khoja A, Alnawawi A, Alnawawi A, Maghrabi A, Altaf A, Aljiffry M. Surgical site infection following abdominal surgery: a prospective cohort study. Can J Surg. 2019 Apr 1;62(2):111-117. doi: 10.1503/cjs.004818. PMID: 30907567; PMCID: PMC6440888.
  5. US Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus (MRSA) in Healthcare Settings.
  6. Vermeulen H, van Hattem JM, Storm‐Versloot MN, Ubbink DT, Westerbos SJ. Topical silver for treating infected wounds. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005486. DOI: 10.1002/14651858.CD005486.pub2.
  7. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. Cochrane Database of Systematic Reviews. 2010 Mar 17;(3):CD006478. DOI: 10.1002/14651858.CD006478.pub2.
  8. Bergin S, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005082. DOI: 10.1002/14651858.CD005082.pub2.
  9. Lam TBL, Omar MI, Fisher E, Gillies K, MacLennan S. Types of indwelling urethral catheters for short‐term catheterisation in hospitalised adults. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No.: CD004013. DOI: 10.1002/14651858.CD004013.pub4.